Investor Presentaiton

MRD market is largely untapped INVESTOR 20 DAY 23 15M+ $20B+ <3% Total Patients Total Addressable Market Current Testing Penetration GUARDANT™ Early + late stage monitoring TAM inclusive of stages II-IV and some stage I, depending on cancer type Revenue is based on 2026 projected ASP 88

View entire presentation